Company / Depreciation & Amortization
Taysha Gene Therapies, Inc. Depreciation & Amortization History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.4M
FY2024
5-year range
$492.0K / $1.4M
FY2020-FY2024
Trend
+17.0%
vs FY2023
Sector context
#115 of 168
Health Care
What the data says
At $1M, Taysha Gene Therapies, Inc.'s depreciation & amortization ranks #54 of 168 in the Health Care sector. Increased from $492,000 to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2024 with a 3-year CAGR of +40.7%.
Increased from $492,000 to $1M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +40.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#54 of 168 in Health CareTop 32% of 168This company $1.4M Sector average $212.9M
▼
-99.4% below sector average
Key checks
Key Insights
- 3-year CAGR of +40.7%, indicating consistent growth.
- In FY2024, depreciation & amortization increased 17.0% year-over-year.
- Ranks #115 out of 168 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.4M | +17.0% |
| FY2023 | $1.2M | +138.2% |
| FY2022 | $492.0K | +0.0% |
| FY2021 | $492.0K | +5366.7% |
| FY2020 | $9.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026